Chikungunya vaccine safety checked in pregnant women

NCT ID NCT07414524

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Valneva Austria GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study follows 200 pregnant women in Brazil who received the chikungunya vaccine (VLA1553) during pregnancy or shortly before. Researchers will track pregnancy and infant health up to 12 weeks after birth, comparing them to a similar group of women who got routine vaccines. The goal is to see if the vaccine is safe for both mother and baby.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Live-attenuated chikungunya virus vaccine (VLA1553)
What this could lead to: If successful, this study could provide important safety data on the chikungunya vaccine for pregnant women, helping guide vaccination recommendations.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. The study is small (200 participants) and only looks at short-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chikungunya prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHIKUNGUNYA VIRUS INFECTION

Contacts and locations

Locations

Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus

Laranjeiras, Sergipe, 49060-025, Brazil
Fundação Faculdade Regional De Medicina De São José Do Rio Preto

São Pedro, São Paulo, 15090-000, Brazil
Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras

Belo Horizonte, Minas Gerais, 31270-901, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.